Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Silence Therapeutics (SLN) over the last 5 years, with Q3 2025 value amounting to -$10.9 million.

  • Silence Therapeutics' Cash from Operations rose 5732.03% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.5 million, marking a year-over-year decrease of 1469.48%. This contributed to the annual value of -$67.6 million for FY2024, which is 3675.14% down from last year.
  • Latest data reveals that Silence Therapeutics reported Cash from Operations of -$10.9 million as of Q3 2025, which was up 5732.03% from -$21.8 million recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' Cash from Operations peaked at $36.4 million during Q2 2021, and registered a low of -$27.5 million during Q4 2024.
  • Over the past 5 years, Silence Therapeutics' median Cash from Operations value was -$11.1 million (recorded in 2022), while the average stood at -$11.4 million.
  • As far as peak fluctuations go, Silence Therapeutics' Cash from Operations plummeted by 42909.49% in 2022, and later surged by 6753.3% in 2024.
  • Over the past 5 years, Silence Therapeutics' Cash from Operations (Quarter) stood at -$3.0 million in 2021, then plummeted by 429.09% to -$15.7 million in 2022, then crashed by 42.66% to -$22.4 million in 2023, then fell by 22.48% to -$27.5 million in 2024, then surged by 60.34% to -$10.9 million in 2025.
  • Its Cash from Operations stands at -$10.9 million for Q3 2025, versus -$21.8 million for Q2 2025 and -$12.3 million for Q1 2025.